GlassScriptPhysician profile
Christopher T Horner
NPI 1124452370
$1,857.47
in general payments reported to CMS, 2019-2025
22 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $115 · 2023: $517 · 2024: $541 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $463.79 | 2021-2024 | |
| Lilly USA, LLC | $376.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $199.15 | 2021-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $142.43 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $102.34 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $88.42 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $84.61 | 2023-2025 | |
| Exact Sciences Corporation | $67.34 | 2023-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $54.54 | 2025 | Vivitrol |
| Abbott Laboratories | $40.27 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.37 | 2023-2024 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $32.01 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.20 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $26.42 | 2021-2023 | Farxiga |
| Daiichi Sankyo INC. | $18.45 | 2024 | Injectafer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $17.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.15 | 2021 | |
| Dexcom, INC. | $14.42 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $13.35 | 2023 | Trintellix |
| Neurocrine Biosciences, INC. | $13.27 | 2021 | |
| Eisai INC. | $11.57 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.15 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Horner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.